Pharmacology of Movement Flashcards

1
Q

what does parkinson’s disease histologically look like

A
  • Loss of dopaminergic cells in substantia nigra pars compacta
  • And presence in neurones of Lewy bodies ( these are intracellular formation that are enriched in the protein alpha-synuclein)
  • These Lewy bodies are also presence in other conditions such as dementia
  • There are also losses of cells throughout the nervous system
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How can you monitor the loss of dopaminergic nigral cells in parkinsons

A
  • This imaging of the transporter is known as the DAT scan

- The transporter is a marker of dopaminergic projections and can be labelled with SPECT ligands

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the motor features of parkinsons

A

Features of the disease
- Resting tremor – specific frequency of around 4-6hz
- Bradykinesia (akinesia)
- Rigidity
They also have
- Difficulty initiating and stopping movement
- Altered gait and postural changes (flexed posture)
Other symtpoms
- Gradual development of micrographia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the non motor features of parkinsons

A
  • olfactory dysfunction
  • depression
  • psychotic symptoms
  • cognitive dysfunction
  • dementia (late phase)
  • sleep disturbance
  • autonomic dysfunction
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what features of parkinsons arise first normally motor or non motor

A

non-motor features may precede by 12-15 years the onset of typical parkinsonian motor symptoms, this premotor phase is likely to involve multiple regions of the peripheral and central nervous system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

describe the scoring phase of parkinsons

A
  • 100%-Completely independent. Able to do all chores w/o slowness, difficulty, or impairment.
  • 90%-Completely independent. Able to do all chores with some slowness, difficulty, or impairment. May take twice as long.
  • 80%-Independent in most chores. Takes twice as long. Conscious of difficulty and slowing
  • 70%-Not completely independent. More difficulty with chores. 3 to 4X along on chores for some. May take large part of day for chores.
  • 60%-Some dependency. Can do most chores, but very slowly and with much effort. Errors, some impossible
  • 50%-More dependant. Help with 1/2 of chores. Difficulty with everything
  • 40%-Very dependant. Can assist with all chores but few alone
  • 30%-With effort, now and then does a few chores alone of begins alone. Much help needed
  • 20%-Nothing alone. Can do some slight help with some chores. Severe invalid
  • 10%-Totally dependant, helpless
  • 0%-Vegetative functions such as swallowing, bladder and bowel function are not functioning. Bedridden.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

what protein is associated with parkinsons

A

protein alpha-synuclein

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what gene is associated with parkinson’s disease

A
  • SNCA- codes for the protein alpha-synuclein – increases significantly the risk of developing Parkinson’s
  • Duplications, or triplications can cause autosomal dominant familial parkinsons disease
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

describe how neurotoxins and dopamine receptors can lead to parkinsons

A
  • there can be mitochondrial toxicity
  • MPTP this can be transformed into the metabolite MPP+ which is neurotoxic for dopaminergic neurones
  • dysfunction of complex I of the mitochondrial respiratory chain can lead to increased oxidative stress
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Why is oxidative stress increased in parkinsons disease

A
  • Dopamine is highly oxidizable and its metabolism produces free radicals and oxidation products such as H2O2
  • MAO – monoamine oxidase (B isoform) is critically involved in oxidation
    processes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

describe the pathway of dopamine synthesis

A
  • L tyrosine is made into L dopa via tyrosine hydroxylase

- L dopa is made into dopamine via DOPA decarboxylase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

describe the pathway of dopamine being degraded

A
  • MAO coverts dopamine to DOPA

- then COMT coverts DOPA to its inactive form

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

why is dopamine given as L dopa in a drug

A
  • dopamine does not go straight through the blood brain barrier as it is hydrophilic
  • when it is taken in high amounts it also makes you sick
  • it is inactivated as well
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What type of receptors are dopamine receptors

A

G protein coupled receptors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

name the two dopamine family receptors and there subtypes

A
  • D1-like (D1 family) receptor subtypes: D1 and D5

- D2-like (D2 family) receptor subtypes: D2, D3, D4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

describe L dopa and what is it combined with

A
  • L-DOPA (levodopa) is a biosynthetic precursor – is combined with peripherally acting DOPA decaboxylase inhibitors (carbidopa, benserazide)
17
Q

name some dopaminergic agonists

A

ropinirole, pramipexole, rotigotine, pergolide, bromocriptine, cabergoline

18
Q

What is rotigotine

A

Rotigotine: dopamine agonist which can be used as transdermal patch – important as the disease progresses and they can no longer swallow

19
Q

What is apomorphine

A

dopamine agonist which can be used as an infusion, for major motor fluctuations

20
Q

name some MAOb inhibitors

A

• MAOB inhibitors (protect residual dopamine against oxidation)
- rasagiline, selegiline

21
Q

name some anticholinergic compounds

A

• Anticholinergic (antimuscarinic) compounds (dopamine loss leads to hyperactivity of cholinergic cells)
- orphenadrine, procyclidine, trihexyphenidyl

22
Q

what does amantadine do

A

• Amantadine (inhibits dopamine reuptake, increases dopamine release)

23
Q

give some examples of COMT inhibitors

A

• COMT inhibitors (used in combination with L-DOPA, to enhance its effects)
- entacapone, tolcapone

24
Q

Name the adverse effects of L dopa

A
  • Nausea and vomiting
  • Postural hypotension
  • Psychosis
  • Impulse- control disorders
  • Excessive day-time sleepiness

Motor complications

  • One off effect – loose efficacy – mobile one moment and then inmobile
  • Wearing off (end of dose deterioration)
  • Dyskinesia, dystonia
25
Q

name the initial therapy for early parkinsons disease

A

L dopa
dopamine agonists
MAOb inhibitors

26
Q
describe 
- L dopa 
- dopamine agonists 
- MAOb inhibitors 
in terms of 
- motor system control 
- risk of side effects
A
  • L dopa - increases motor system control most 0 increase risk of motor complications and other adverse events
  • dopamine agonists - increases motor system control the 2nd most - decrease risk of motor complications but has other adverse effects
  • MAOb inhibitors - increases motor system control the least - decrease risk of motor complications but has other adverse effects
27
Q

describe how a diagnosis of parkinsons is made

A
  • mild motor disability and no cognitive impairment - begin MAOb inhibitor
  • mild/moderate motor disability and no cognitive impairment - begin dopamine agonist
  • moderate/severe disability and age 70-75+ years or with significant comorbidity including cognitive impairment - begin L Dopa and plus or minus COMT inhibitor
28
Q

what should parkinsons patient have regular access to

A
  • Monitoring and alteration of medication
  • A continuing point of contact
  • A reliable source of information
  • physiotherapy, speech and language therapy, and occupational therapy should be available, as supportive interventions in the management of these patients
29
Q

name other treatment for parkinsons

A
  • long term survivial of human embryonic mesencephalic graft in parkisnons disease, - the graft is functional and releases dopamine (after administration of metamphetamine) the dopamine released by the graft can displace the radioalabelled raclopride
30
Q

what gene defect is in huntingtons disease

A

associated with changes in the gene encoding the protein huntington on chromosome 4
- The gene presents with an abnormal number of repeats of glutamine (CAG codon) in the protein sequence; abnormal gene contains >36 repeats; the mutation leads to a “gain of function”; the mutated protein aggregates inside cells

31
Q

What are the pathological changes in huntingtons

A
  • Cortical atrophy and prominent striatal degradation

- Loss of medium size spiny neurones (striato-pallidal and striato-nigral pathways)

32
Q

What is the mechanism underlying neurodegeneration in huntington’s disease

A
  • Excitotoxicity
  • Loss of neurotrophic factors
  • Accumulation of aggregates of mutant huntingtin protein
  • Dysregulation of transcription
  • Increased oxidative stress
  • Abnormalities in axonal transport
  • Synaptic abnormalities
33
Q

How long does huntingtons disease take to progress

A

The disease progresses over about 12-15 years from onset

34
Q

What are the symptoms of Huntington’s disease

A
  • Choreic movement (early to mid-stage disease)
  • Gait abnormalities
  • Lack of coordination
  • Cognitive impairment: poor attention, memory difficulties
  • Psychiatric disturbances
  • Sleep disturbance
  • Weight loss
35
Q

what is the pharacological management of Huntington’s disease

A
  • Vesicular amine transporter inhibitor: tetrabenazine- blcoks the concentration of dopamine in vesicles
  • Antidopaminergic (antipsychotic) drugs: haloperidol, olanzapine
  • Antidepressant drugs: imipramine, amitriptyline